Vanda Pharmaceuticals: SG&A Takes Off, TAM Doesn't (Rating Downgrade) [Seeking Alpha]
Vanda Pharmaceuticals Inc. (VNDA)
Last vanda pharmaceuticals inc. earnings: 2/25 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=196233&p=irol-irhome
Company Research
Source: Seeking Alpha
NEREUS's FDA approval for motion-induced vomiting prevention is commercially limited by undifferentiated efficacy, entrenched generics, and niche application. VNDA's Q3 showed 18% revenue growth but a widening net loss, with SG&A costs surging due to heavy direct-to-consumer marketing. Pipeline expansion and increased promotional spend are unlikely to drive near-term operating leverage, with FY25 guidance signaling ongoing cash burn. J Studios/DigitalVision via Getty Images Introduction Vanda Pharmaceuticals Inc.'s stock ( VNDA ) has rallied 74% since my last look at the small-cap pharma company. Back in September 2024, Vanda was the subject of M&A activity, having received multiple takeover bids in June 2024 for “generous premiums.” Vanda's portfolio is, in my This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hour
Show less
Read more
Impact Snapshot
Event Time:
VNDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VNDA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VNDA alerts
High impacting Vanda Pharmaceuticals Inc. news events
Weekly update
A roundup of the hottest topics
VNDA
News
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vanda Pharmaceuticals Inc. - VNDAGlobeNewswire
- Vanda Pharmaceuticals Says FDA Rejects Hetlioz as Jet Lag Treatment [Yahoo! Finance]Yahoo! Finance
- Vanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag DisorderPR Newswire
- Assessing Vanda Pharmaceuticals (VNDA) Valuation After FDA Approval Of NEREUS For Motion Sickness [Yahoo! Finance]Yahoo! Finance
- Vanda Pharmaceuticals (NASDAQ:VNDA) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
VNDA
Earnings
- 10/29/25 - Miss
VNDA
Sec Filings
- 1/9/26 - Form SCHEDULE
- 1/8/26 - Form 8-K
- 12/31/25 - Form 8-K
- VNDA's page on the SEC website